Abstract: This disclosure relates to managing cardiovascular diseases and conditions associated with kidney disease. In certain embodiments, this disclosure relates to methods of treating or preventing a cardiovascular disease or condition comprising administering an effective amount of a urea transporter inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with kidney disease. In certain embodiments, the subject is diagnosed with uremic cardiomyopathy. In certain embodiments, the urea transporter inhibitor is N,N?-dimethylthiourea (DMTU), prodrug, derivative, or salt thereof.